Advertisement

Pathology & Oncology Research

, Volume 13, Issue 2, pp 91–96 | Cite as

Expression of cancer-testis antigen CT7 (MAGE-C1) in breast cancer: An immunohistochemical study with emphasis on prognostic utility

  • Stefan Krüger
  • Vladislava Ola
  • Alfred C. Feller
  • Dorothea Fischer
  • Michael Friedrich
Article

Abstract

High expression of the cancer-testis antigen CT7, also referred to as MAGE-C1, has been recently described in a variety of malignant tumors, including breast carcinoma. To our knowledge, no data concerning the prognostic utility of CT7 expression in breast cancer are available. In this retrospective study, we evaluated the relationship between CT7 immunoreactivity and clinicopathological parameters as well as relapse-free survival (RFS) and metastasis-free survival (MFS) of 124 women with invasive breast cancer. A positive CT7 status, defined as immunoreactivity in more than 50% of tumor cells, was found in 18% of cases and correlated significantly with high tumor grade (p=0.004), but with no other clinicopathological parameter. In a univariate analysis, CT7 status showed an association with RFS by trend (p=0.107; relative risk [RR]: 1.85) and a significant association with MFS (p=0.043; RR: 2.02). In a multivariate analysis, tumor grade, stage, nodal status, angioinvasion, HER2 expression as well as estrogen and progesterone receptor expression were identified as significant independent prognostic factors of RFS and/or MFS. In this respect, CT7 expression showed a weak, statistically not significant trend towards an independent prognostic relevance concerning prediction of MFS (p=0.147; RR: 1.95). Our data suggest that estimation of CT7 immunoreactivity is of limited prognostic usefulness in breast cancer. It may provide additional information concerning assessment of MFS in selected cases.

Key words

breast cancer cancer-testis antigen CT7 MAGE-C1 prognosis immunohistochemistry 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Van den Eynde BJ, van der Bruggen P: T cell defined tumor antigens. Curr Opin Immunol 9: 684–693, 1997.PubMedCrossRefGoogle Scholar
  2. 2.
    Takahashi K, Shichijo S, Noguchi M, et al: Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res 55: 3478–3482, 1995.PubMedGoogle Scholar
  3. 3.
    Scanlan MJ, Gure AO, Jungbluth AA, et al: Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188: 22–32, 2002.PubMedCrossRefGoogle Scholar
  4. 4.
    Suri A: Cancer testis antigens — their importance in immunotherapy and in the early detection of cancer. Expert Opin Ther 6: 379–389, 2006.CrossRefGoogle Scholar
  5. 5.
    Marchand M, van Baren N, Weiynants P, et al: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 18: 219–230, 1999.CrossRefGoogle Scholar
  6. 6.
    Banchereau J, Palucka AK, Dhodapkar M, et al: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dentritic cell vaccine. Cancer Res 61:6451–6458, 2001.PubMedGoogle Scholar
  7. 7.
    Coulie PG, Karanikas V, Colau D, et al: A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 98: 10290–10295, 2001.PubMedCrossRefGoogle Scholar
  8. 8.
    Bettinotti MP, Panelli MC, Ruppe E, et al: Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170–178. Int J Cancer 105: 210–216, 2003.PubMedCrossRefGoogle Scholar
  9. 9.
    Marchand M, Punt CJ, Aamdal S, et al: Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 39: 70–77, 2003.PubMedCrossRefGoogle Scholar
  10. 10.
    Kruit WH, van Ojik HH, Brichard VG, et al: Phase 1/2 study of subcutaneous and intradermal immunization with recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 117: 596–604, 2005.PubMedCrossRefGoogle Scholar
  11. 11.
    van Baren N, Bonnet MC, Dreno B, et al: Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 23: 9008–9021, 2005.PubMedCrossRefGoogle Scholar
  12. 12.
    Sadanaga N, Nagashima H, Mashino K, et al: Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 7: 2277–2284, 2001.PubMedGoogle Scholar
  13. 13.
    Russo V, Traversari C, Verrecchia A, et al: Expression of the MAGE gene family in primary and metastatic human breast cancer: implications for tumor antigen-specific immunotherapy. Int J Cancer 64: 216–221, 1995.PubMedCrossRefGoogle Scholar
  14. 14.
    Jungbluth AA, Chen YT, Busam KJ, et al: CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues. Int J Cancer 99: 839–845, 2002.PubMedCrossRefGoogle Scholar
  15. 15.
    Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403–410, 1991.PubMedCrossRefGoogle Scholar
  16. 16.
    Chitale DA, Jungbluth AA, Marshall DS, et al: Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray. Mod Pathol 18: 119–126, 2005.PubMedCrossRefGoogle Scholar
  17. 17.
    Early Breast Cancer Trialists’ Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930–942, 1998.CrossRefGoogle Scholar
  18. 18.
    Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451–1467, 1998.CrossRefGoogle Scholar
  19. 19.
    Danish Breast Cancer Cooperative Group: Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group BBCG 82b and c randomized studies. J Clin Oncol: 24: 2268–2275, 2006.CrossRefGoogle Scholar
  20. 20.
    Yamanaka K, Miyake H, Hara I, et al: Expression of MAGE genes in renal cell carcinoma. Int J Mol Med 2: 57–60, 1998.PubMedGoogle Scholar
  21. 21.
    Patard JJ, Brasseur F, Gil-Diez S, et al: Expression of MAGE genes in transitional cell carcinomas of the urinary bladder. Int J Cancer 64: 60–64, 1995.PubMedCrossRefGoogle Scholar
  22. 22.
    Toh Y, Yamana H, Shichijo S, et al: Expression of MAGE-1 gene by esophageal carcinomas. Jpn J Cancer Res 86: 714–717, 1995.PubMedGoogle Scholar
  23. 23.
    Nagao T, Higashitsuji H, Nonoguchi K, et al: MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J Biol Chem 278: 10668–10674, 2003.PubMedCrossRefGoogle Scholar
  24. 24.
    Peikert T, Specks U, Farver C, et al: Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis. Cancer Res 66: 4693–4700, 2006.PubMedCrossRefGoogle Scholar
  25. 25.
    Monte M, Simonatto M, Peche LY, et al: MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 103: 11160–11165, 2006.PubMedCrossRefGoogle Scholar
  26. 26.
    Riker A, Cormier J, Panelli M, et al: Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126: 112–120, 1999.PubMedGoogle Scholar
  27. 27.
    El-Shami K, Tirosh B, Bar-Haim E, et al: MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur J Immunol 29: 3295–3301, 1999.PubMedCrossRefGoogle Scholar
  28. 28.
    Markiewicz MA, Fallarino F, Ashikari A, et al: Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int Immunol 13: 625–632, 2001.PubMedCrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2007

Authors and Affiliations

  • Stefan Krüger
    • 1
  • Vladislava Ola
    • 1
  • Alfred C. Feller
    • 1
  • Dorothea Fischer
    • 2
  • Michael Friedrich
    • 2
  1. 1.Institute of PathologyUniversity of Schleswig-HolsteinLübeckGermany
  2. 2.Department of Gynecology and ObstetricsUniversity of Schleswig-HolsteinLübeckGermany

Personalised recommendations